{"id":49642,"date":"2025-12-01T22:40:29","date_gmt":"2025-12-01T14:40:29","guid":{"rendered":"https:\/\/flcube.com\/?p=49642"},"modified":"2025-12-01T22:40:30","modified_gmt":"2025-12-01T14:40:30","slug":"imugene-and-jw-therapeutics-partner-to-evaluate-oncarlytics-car%e2%80%91t-combination-for-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49642","title":{"rendered":"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>Imugene Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/IMU:ASX\">ASX: IMU<\/a>) and <strong>JW Therapeutics (Shanghai) Co., LTD<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2126:HKG\">HKG: 2126<\/a>) announced a co\u2011development collaboration to evaluate the combination of Imugene\u2019s <strong>oncolytic virus CF33\u2011CD19 (onCARlytics)<\/strong> and JW\u2019s <strong>Carteyva<\/strong>\u2014a CD19\u2011directed autologous CAR\u2011T cell therapy\u2014for patients with advanced solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-overview\">Collaboration Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Imugene Ltd (ASX:IMU) + JW Therapeutics (HKEX:2126)<\/td><\/tr><tr><td><strong>Imugene Asset<\/strong><\/td><td>CF33\u2011CD19 (onCARlytics) \u2013 oncolytic virus engineered to express CD19<\/td><\/tr><tr><td><strong>JW Asset<\/strong><\/td><td>Carteyva \u2013 anti\u2011CD19 autologous CAR\u2011T cell therapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors (multiple histologies)<\/td><\/tr><tr><td><strong>Strategy<\/strong><\/td><td><em>Mark and Kill<\/em>: Virus induces CD19 on tumor cells \u2192 CAR\u2011T mediated clearance<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>China\u2011only clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-innovation\">Mechanism of Action &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transformative Approach<\/strong>: onCARlytics infects solid tumor cells, forcing ectopic CD19 expression that is normally absent in non\u2011hematologic cancers.<\/li>\n\n\n\n<li><strong>Dual\u2011Agent Synergy<\/strong>: Carteyva CAR\u2011T cells recognize de novo CD19 epitopes, triggering potent T\u2011cell cytotoxicity while the virus continues oncolytic replication.<\/li>\n\n\n\n<li><strong>Preclinical Validation<\/strong>: In vivo models show >80\u202f% tumor regression versus monotherapy controls; enhanced T\u2011cell persistence at tumor sites.<\/li>\n\n\n\n<li><strong>IP Position<\/strong>: Imugene holds global patents on CD19\u2011transgene\u2011armed oncolytic poxviruses; JW contributes proprietary CAR\u2011T manufacturing know\u2011how.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-roadmap\">Clinical Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activities<\/th><th>Timeline<\/th><th>Key Endpoints<\/th><\/tr><\/thead><tbody><tr><td><strong>Preclinical<\/strong><\/td><td>In vitro co\u2011culture killing assays; orthotopic mouse models<\/td><td>Q1\u202f2026<\/td><td>Synergy confirmation, dosing schema<\/td><\/tr><tr><td><strong>Phase\u202f1<\/strong><\/td><td>Investigator\u2011initiated trial (IIT) at premier Chinese CAR\u2011T centers<\/td><td>H2\u202f2026 \u2013 H2\u202f2027<\/td><td>Safety, CD19 induction rates, ORR, DLTs<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Expansion cohorts; potential registrational path in China<\/td><td>2028+<\/td><td>PFS, OS, biomarker\u2011driven patient selection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-implications\">Strategic Context &amp; Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China CAR\u2011T Leadership<\/strong>: JW Therapeutics is the first company to commercialize a CAR\u2011T product in China (relma-cel); dominates the domestic cell\u2011therapy infrastructure.<\/li>\n\n\n\n<li><strong>Solid Tumor Unmet Need<\/strong>: Current CAR\u2011T therapies show limited efficacy in solid tumors due to antigen heterogeneity; the <em>Mark and Kill<\/em> paradigm could unlock a >US$10\u202fbillion global market.<\/li>\n\n\n\n<li><strong>Revenue Upside<\/strong>: If Phase\u202f1 succeeds, JW gains exclusive China rights; Imugene eligible for milestones + double\u2011digit royalties. Analysts estimate peak China sales potential of <strong>\u00a52.5\u202fbillion<\/strong> (\u2248\u202fUS$350\u202fmillion) for the combination.<\/li>\n\n\n\n<li><strong>Competitive Moat<\/strong>: No approved oncolytic\u2011CAR\u2011T combos exist; first\u2011mover advantage in China could set the global standard.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding preclinical results, trial initiation timelines, and commercial potential. Actual outcomes may vary due to regulatory, clinical, and competitive risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co\u2011development&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49645,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[4482,21,29,1165,4481],"class_list":["post-49642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-asx-imu","tag-car-t","tag-combination-therapy","tag-hkg-2126","tag-imugene"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co\u2011development collaboration to evaluate the combination of Imugene\u2019s oncolytic virus CF33\u2011CD19 (onCARlytics) and JW\u2019s Carteyva\u2014a CD19\u2011directed autologous CAR\u2011T cell therapy\u2014for patients with advanced solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49642\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co\u2011development collaboration to evaluate the combination of Imugene\u2019s oncolytic virus CF33\u2011CD19 (onCARlytics) and JW\u2019s Carteyva\u2014a CD19\u2011directed autologous CAR\u2011T cell therapy\u2014for patients with advanced solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49642\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-01T14:40:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T14:40:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors\",\"datePublished\":\"2025-12-01T14:40:29+00:00\",\"dateModified\":\"2025-12-01T14:40:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0102-1.webp\",\"keywords\":[\"ASX: IMU\",\"CAR-T\",\"Combination therapy\",\"HKG: 2126\",\"Imugene\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49642#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49642\",\"name\":\"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0102-1.webp\",\"datePublished\":\"2025-12-01T14:40:29+00:00\",\"dateModified\":\"2025-12-01T14:40:30+00:00\",\"description\":\"Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co\u2011development collaboration to evaluate the combination of Imugene\u2019s oncolytic virus CF33\u2011CD19 (onCARlytics) and JW\u2019s Carteyva\u2014a CD19\u2011directed autologous CAR\u2011T cell therapy\u2014for patients with advanced solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49642\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0102-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0102-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49642#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co\u2011development collaboration to evaluate the combination of Imugene\u2019s oncolytic virus CF33\u2011CD19 (onCARlytics) and JW\u2019s Carteyva\u2014a CD19\u2011directed autologous CAR\u2011T cell therapy\u2014for patients with advanced solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49642","og_locale":"en_US","og_type":"article","og_title":"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors","og_description":"Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co\u2011development collaboration to evaluate the combination of Imugene\u2019s oncolytic virus CF33\u2011CD19 (onCARlytics) and JW\u2019s Carteyva\u2014a CD19\u2011directed autologous CAR\u2011T cell therapy\u2014for patients with advanced solid tumors.","og_url":"https:\/\/flcube.com\/?p=49642","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-01T14:40:29+00:00","article_modified_time":"2025-12-01T14:40:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49642#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49642"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors","datePublished":"2025-12-01T14:40:29+00:00","dateModified":"2025-12-01T14:40:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49642"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49642#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102-1.webp","keywords":["ASX: IMU","CAR-T","Combination therapy","HKG: 2126","Imugene"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49642#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49642","url":"https:\/\/flcube.com\/?p=49642","name":"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49642#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49642#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102-1.webp","datePublished":"2025-12-01T14:40:29+00:00","dateModified":"2025-12-01T14:40:30+00:00","description":"Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co\u2011development collaboration to evaluate the combination of Imugene\u2019s oncolytic virus CF33\u2011CD19 (onCARlytics) and JW\u2019s Carteyva\u2014a CD19\u2011directed autologous CAR\u2011T cell therapy\u2014for patients with advanced solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49642#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49642"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49642#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102-1.webp","width":1080,"height":608,"caption":"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49642#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR\u2011T Combination for Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0102-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49642"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49642\/revisions"}],"predecessor-version":[{"id":49646,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49642\/revisions\/49646"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49645"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}